China: Cooperation Fresenius Kabi and Vifor Pharma Create Joint Venture
Fresenius Kabi and Vifor Pharma have formed a joint venture in China to provide patients access to vital blood management treatment.
Bad Homburg/Germany — A newly established joint venture between Fresenius Kabi and Vifor Pharma is to combine Vifor Pharma’s intravenous drug portfolio for the treatment of iron deficiency with Fresenius Kabi’s long-year presence in the market to benefit both patients and the healthcare system in China.
The joint venture will focus on marketing, market access and medical affairs activities whereas the German healthcare company will be fully responsible for the commercialization of the intravenous iron portfolio. The joint company will be 55 % owned by Vifor Pharma and 45 % by Fresenius Kabi. Financial terms were not disclosed.
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 46376671)